General
Legacy ID
1
April 2016 Effects Report
April 2016 Effects Report
DOT FY15 SCI Analysis Plan
This document is the DOT FY15 SCI Analysis Plan. For more information, contact Diane Morrison @ 202-366-4960 or diane.morrison@dot.gov.
DOT FY14 SCI Analysis Report
This document is the DOT FY14 SCI Analysis Report. For more information, contact Diane Morrison @ 202-366-4960 or diane.morrison@dot.gov.
FY 2015 DOT SCI Supplemental Data
This document is the FY 2015 DOT SCI Supplemental Data. For more information, contact Diane Morrison @ 202-366-4960 or diane.morrison@dot.gov.
DOT FY15 Appendix C Summary
This document is the DOT FY 2015 Appendix C Summary. For more information, contact Diane Morrison @ 202-366-4960 or diane.morrison@dot.gov.
DOT FY 2015 Service Contract Inventory Detail Level
This document is the DOT FY 2015 Service Contract Inventory Detail Level. For more information, contact Diane Morrison @ 202-366-4960 or diane.morrison@dot.gov.
DOT Rule 49 CFR Part 40 Section 40.155
Subpart G - Medical Review Officers and the Verification Process§ 40.155 What does the MRO do when a negative or positive test result is also dilute?
(a) When the laboratory reports that a specimen is dilute, you must, as the MRO, report to the DER that the specimen, in addition to being...
DOT Rule 49 CFR Part 40 Section 40.153
Subpart G - Medical Review Officers and the Verification Process § 40.153 How does the MRO notify employees of their right to a test of the split specimen?(a) As the MRO, when you have verified a drug test as positive for a drug or drug metabolite, or as a refusal to test because of...
DOT Rule 49 CFR Part 40 Section 40.151
Subpart G - Medical Review Officers and the Verification Process § 40.151 What are MROs prohibited from doing as part of the verification process?As an MRO, you are prohibited from doing the following as part of the verification process:
(a) You must not consider any evidence (...